^
Association details:
| Biomarker: | SP140 overexpression |
|---|---|
| Cancer: | Thymic Carcinoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
Published date:
12/13/2022
Excerpt:
Examining the datasets of patients with recurrent glioblastoma who underwent neoadjuvant anti-PD-1 therapy and patients with thymic carcinoma who underwent anti-PD-1 therapy, we found that higher levels of SP140 were associated with a favorable response to the neoadjuvant anti-PD-1 therapy in recurrent glioblastoma and a favorable response to anti-PD-1 in thymic carcinoma.
DOI:
10.1136/jitc-2022-005088
